Searching On:

Disease:

Gene:

EGFR, L858R (c.2573T>G)

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse EGFR  - General Description The EGFR gene encodes for a cell-surface protein known as the epidermal growth factor receptor, which is found in many normal epithelial tissues such as the skin and hair follicles. When members of the epidermal growth factor family attach to EGFR, they activate several different cell signaling pathways that control various cell functions, including cell growth. Mutations in EGFR can lead to unregulated activation of the protein. These types of activating mutations are often found in NSCLC (non-small cell lung cancer), glioblastoma and head and neck squamous cell carcinoma. Sometimes, excess EGFR protein is produced due to the presence of too many copies of the EGFR gene, leading to excessive cell division and growth in the presence of epidermal growth factor. Among the human cancers in which EGFR overabundance is present are cancers of the head and neck (squamous cell), colon, rectum, lung (NSCLC), central nervous system (glioblastoma), pancreas and breast (HER2-positive metastatic). Blocking EGFR in tumors may keep cancer cells from growing. The FDA has approved several therapies that target EGFR in one or more cancers. Tumor mutation profiling performed clinically at the MGH Cancer Center has indicated that EGFR mutations occur primarily in lung cancer (~15%), but also in a minor subset of gastric (2%), brain (1%) and pancreatic (1%) cancers. Source: Genetics Home ReferenceThe epidermal growth factor receptor (EGFR) gene encodes for a cell-surface protein that belongs to the ERBB family of receptor tyrosine kinases. Four members of the ERBB family have been identified: EGFR (ERBB1, HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). Binding of a ligand induces ERBB receptor homo-/hetero-dimerization and triggers a signaling cascade that drives many cellular responses. These include the activation of PI3K-AKT/mTOR and MAP kinase/ERK pathways, which promote cell survival and proliferation. EGFR mutations have been most frequently associated with non-small cell lung cancer, but have also been described in other malignancies including gliomas, head and neck, prostate and ovarian tumors. Tumor mutation profiling performed clinically at the MGH Cancer Center has indicated that EGFR mutations occur primarily in lung cancer (~15%), but also in a minor subset of gastric (2%), brain (1%) and pancreatic (1%) cancers. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
The EGFR gene encodes for a cell-surface protein known as the epidermal growth factor receptor, which is found in many normal epithelial tissues such as the skin and hair follicles. When members of the epidermal growth factor family attach to EGFR, they activate several different cell signaling pathways that control various cell functions, including cell growth.

Mutations in EGFR can lead to unregulated activation of the protein. These types of activating mutations are often found in NSCLC (non-small cell lung cancer), glioblastoma and head and neck squamous cell carcinoma. Sometimes, excess EGFR protein is produced due to the presence of too many copies of the EGFR gene, leading to excessive cell division and growth in the presence of epidermal growth factor. Among the human cancers in which EGFR overabundance is present are cancers of the head and neck (squamous cell), colon, rectum, lung (NSCLC), central nervous system (glioblastoma), pancreas and breast (HER2-positive metastatic). Blocking EGFR in tumors may keep cancer cells from growing. The FDA has approved several therapies that target EGFR in one or more cancers.

Tumor mutation profiling performed clinically at the MGH Cancer Center has indicated that EGFR mutations occur primarily in lung cancer (~15%), but also in a minor subset of gastric (2%), brain (1%) and pancreatic (1%) cancers.

Source: Genetics Home Reference
The epidermal growth factor receptor (EGFR) gene encodes for a cell-surface protein that belongs to the ERBB family of receptor tyrosine kinases. Four members of the ERBB family have been identified: EGFR (ERBB1, HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). Binding of a ligand induces ERBB receptor homo-/hetero-dimerization and triggers a signaling cascade that drives many cellular responses. These include the activation of PI3K-AKT/mTOR and MAP kinase/ERK pathways, which promote cell survival and proliferation. EGFR mutations have been most frequently associated with non-small cell lung cancer, but have also been described in other malignancies including gliomas, head and neck, prostate and ovarian tumors.

Tumor mutation profiling performed clinically at the MGH Cancer Center has indicated that EGFR mutations occur primarily in lung cancer (~15%), but also in a minor subset of gastric (2%), brain (1%) and pancreatic (1%) cancers.

Source: Genetics Home Reference
PubMed ID's
15864276, 15118073, 15118125, 15329413, 18772890, 15837736, 16720329, 21057220
Expand Collapse L858R (c.2573T>G)  in EGFR
The EGFR L858R mutation arises from the nucleotide change c.2573T>G in exon 21, resulting in an amino acid substitution of the leucine (L) at position 858 by an arginine (R).
The EGFR L858R mutation arises from the nucleotide change c.2573T>G in exon 21, resulting in an amino acid substitution of the leucine (L) at position 858 by an arginine (R).

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: Showing Results: 1-10 of 14 Per Page:
12Next »
Protocol # Title Location Status Match
NCT02108964 A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies MGH Open GM
NCT02716116 A Trial of AP32788 in Non-Small Cell Lung Cancer A Trial of AP32788 in Non-Small Cell Lung Cancer MGH Open GM
NCT01553942 Afatinib With CT and RT for EGFR-Mutant NSCLC Afatinib With CT and RT for EGFR-Mutant NSCLC MGH Open GM
NCT01953926 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification MGH Open GM
NCT02143466 AZD9291 in Combination With Ascending Doses of Novel Therapeutics AZD9291 in Combination With Ascending Doses of Novel Therapeutics MGH Open GM
NCT02193282 Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) MGH Open GM
NCT02335944 Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. MGH Open GM
NCT02573324 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification MGH Open G
NCT01633970 A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors MGH Open G
NCT02520778 Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer MGH Open G
Trial Status: Showing Results: 1-10 of 14 Per Page:
12Next »

Share with your Physican

Print information for your Physician.

Print information